Arvinas Inc - Asset Resilience Ratio
Arvinas Inc (ARVN) has an Asset Resilience Ratio of 70.15% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ARVN working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2025)
This chart shows how Arvinas Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see ARVN asset base.
Liquid Assets Composition Over Time
This chart breaks down Arvinas Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read how much debt does Arvinas Inc carry for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $473.60 Million | 70.15% |
| Total Liquid Assets | $473.60 Million | 70.15% |
Asset Resilience Insights
- Very High Liquidity: Arvinas Inc maintains exceptional liquid asset reserves at 70.15% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Arvinas Inc Industry Peers by Asset Resilience Ratio
Compare Arvinas Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH |
Biotechnology | 33.23% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
Annual Asset Resilience Ratio for Arvinas Inc (2016–2025)
The table below shows the annual Asset Resilience Ratio data for Arvinas Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 75.57% | $542.50 Million | $717.90 Million | -10.46pp |
| 2024-12-31 | 86.03% | $938.90 Million | $1.09 Billion | +13.26pp |
| 2023-12-31 | 72.77% | $949.30 Million | $1.30 Billion | -15.82pp |
| 2022-12-31 | 88.59% | $1.12 Billion | $1.27 Billion | +0.43pp |
| 2021-12-31 | 88.16% | $1.39 Billion | $1.58 Billion | +74.19pp |
| 2020-12-31 | 13.97% | $100.20 Million | $717.40 Million | -76.09pp |
| 2019-12-31 | 90.06% | $271.66 Million | $301.64 Million | -2.59pp |
| 2018-12-31 | 92.65% | $184.64 Million | $199.28 Million | +80.30pp |
| 2017-12-31 | 12.35% | $8.26 Million | $66.85 Million | -67.96pp |
| 2016-12-31 | 80.31% | $30.47 Million | $37.94 Million | -- |
About Arvinas Inc
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing… Read more